kidney cancer

Robot linked with improved kidney Ca careKidney cancer patients were more likely to undergo partial nephrectomy when treated in hospitals that were early adopters of robotic surgery, according to a recent report that one leading expert calls “some of the best evidence to date of a favorable impact of surgical robots in urologic care.”
Smoking raises risk of second smoking-related cancerSurvivors of bladder, kidney, and two other forms of cancer who smoked 20 or more cigarettes a day prior to their cancer diagnoses have an up to fivefold higher risk of developing a second smoking-associated cancer compared to survivors of the same cancers who never smoked.
AUA 2014: Studies shine light on new PCa tests, TRT safetyIn our “Best of AUA” report, Urology Times’ editors and writers present the AUA annual meeting’s take-home messages in 15 therapeutic areas.
Best of AUA 2014: Kidney CancerMonish Aron, MD, presents the take home messages on kidney cancer from the AUA annual meeting in Orlando, FL.
Best of AUA 2014: Basic Science ResearchK.C. Balaji, MD, presents the take home messages on basic science research from the AUA annual meeting in Orlando, FL.
Studies reveal genes key to RCC development, growthTwo recently published Mayo Clinic studies provide genetic clues to clear cell renal cell carcinoma that may have important therapeutic implications, researchers say.
Use of robotic RN rising, despite unclear advantagesThe use of robot-assisted radical nephrectomy increased by 6% over a recent 3-year period, and high-volume robotic centers for partial nephrectomy were found more likely to perform robotic radical nephrectomy despite its increased cost and similar complications to laparoscopic radical nephrectomy, according to a recent study.
Robotic radical nephrectomy: Really?None of the comparative studies of robotic radical nephrectomies (RRN) and laparoscopic radical nephrectomies (LRN) has shown benefit of RRN over LRN. Why then are so many minimally invasive RNs performed this way?
Urology Product Preview May 2014Drugs and devices in the pipeline from MEI Pharma, Bayer HealthCare, Merck, Pfizer, and Minomic International.
Urology Product Preview April 2014Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.